IN (Infinit) 24-hour volatility at 109.5%: $6 million seed round completed and surging trading volume drive dramatic fluctuations
Bitget Pulse2026/04/15 16:02Volatility Overview
In the past 24 hours, the price of IN surged from a low of $0.06694 to a high of $0.14022, currently trading at $0.07983, with a price amplitude of 109.5%. The 24-hour trading volume has expanded significantly to approximately $55.78 million (CMC data), a sharp increase from usual levels, indicating increased capital activity.
Brief Analysis of the Abnormal Movement
- Seed round financing completed: On April 15, Infinit completed a $6 million seed round led by an investor. As an AI-driven DeFi abstraction layer project, it has attracted market attention and directly triggered the price surge.
- Unusually large trading volume: 24-hour trading volume reached $55.78 million–$151 million, accompanied by an RSI of 81 (overbought). Early data showed an abnormal 134x volume, suspected to be a case of smart money accumulation and pump.
Market Perspective and Outlook
Market sentiment has turned euphoric, with community discussions focusing on the positive financing news and volume spike. Posts related to Infinit Labs (@Infinit_Labs) show a short-term rally of 16.88%, but the RSI of 81 signals an "euphoric stretch, dump incoming." Analysts recommend waiting for a pullback to $0.06041 to confirm a reversal, avoiding FOMO. If the structure holds, the market may continue to rise; otherwise, there is a risk of a correction.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, for informational purposes only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market
Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.
"Predicting Your Prediction" Intensifies Tech Stock Sell-off! After $2.3 Trillion Market Value Evaporates, Has the "Hot Money" Mechanical Selling Still Not Subsided?
The Nasdaq 100 Index fell by 6.4%, wiping out $2.3 trillion in market capitalization. The core reason behind this decline is concerns that a comprehensive victory by the Democratic Party could lead to stricter regulations on AI development. Systematic funds, which typically follow the stock market's trend and respond to price fluctuations and momentum signals, were thus forced to reduce their investments, accelerating the downturn. The selling pressure from systematic strategies may not be over yet; it is expected that in the coming days, portfolios targeting volatility will sell at least $50 billion worth of stocks.
Crypto prices
More
